Scarica l'app Stockscreener
0.848
6.21%
0.0496
Precedente Chiudi:
$0.7984
Aprire:
$0.7838
Volume 24 ore:
104.84K
Relative Volume:
0.59
Capitalizzazione di mercato:
$872.65K
Reddito:
$104.00K
Utile/perdita netta:
$-8.39M
Rapporto P/E:
-0.00816
EPS:
-103.9477
Flusso di cassa netto:
$-8.31M
1 W Prestazione:
-2.32%
1M Prestazione:
-43.09%
6M Prestazione:
-81.96%
1 anno Prestazione:
-97.03%
Intervallo 1D:
$0.7731
$0.86
Intervallo di 1 settimana:
$0.7553
$0.86
Portata 52W:
$0.7553
$59.40
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Nome
Biodexa Pharmaceuticals Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BDRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
0.848 | 1.30M | 104.00K | -8.39M | -8.31M | -103.95 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-08 | Iniziato | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Borsa (BDRX) Ultime notizie
Biodexa passes halfway mark in Phase 3 trial recruitment for FAP - Investing.com South Africa
Biodexa Pharmaceuticals plc (BDRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Result of Annual General Meeting - Yahoo Finance UK
Biodexa prices $3.5 million offering with warrants - Investing.com
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants - Yahoo Finance UK
symbol__ Stock Quote Price and Forecast - CNN
Biodexa expands Serenta phase 3 trial into Canada By Investing.com - Investing.com India
Biodexa expands Serenta phase 3 trial into Canada - Investing.com
Biodexa Pharmaceuticals plc Sponsored ADR Actuals & Estimates (NASDAQ:BDRX) - TradingView
Postponement and Re-scheduling of Annual General Meeting - markets.businessinsider.com
BDRX News | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
BeOne Medicines Ltd.Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
BDRXBiodexa Pharmaceuticals Plc ADR Latest SEC Filings - Finviz
BDRX Stock Price, Quote & Chart | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Biodexa proposes share capital reorganization at June meeting - Investing.com UK
Biodexa issues letter to Shareholders - markets.businessinsider.com
Biodexa proposes share capital reorganization at June meeting By Investing.com - Investing.com Nigeria
Biodexa plans to shrink 373B shares without cutting ADS stakes - Stock Titan
BDRX Stock Jumps As Biodexa ADRs Lead Biotech Rally - StocksToTrade
BDRX Stock Jumps As ADR Momentum Attracts Active Traders - timothysykes.com
Biodexa Pharmaceuticals surges on pre-market trading - Intellectia AI
Inventory turnover of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
What Makes Haleon PLC Sponsored ADR (HLN) a New Buy Stock - Yahoo Finance
Net income before discontinued operations of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Book value per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Biodexa Pharmaceuticals plc Sponsored ADR Cash Flow – FWB:5MP2 - TradingView — Track All Markets
Net debt of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Basic earnings per share (basic EPS) of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Price to earnings ratio of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Who's Buying or Selling Biodexa Pharmaceuticals PLC (STU:5MP2) Stock Today? - GuruFocus
Biodexa Pharmaceuticals Plc: Shareholders Board Members Managers and Company Profile | US59564R8723 - marketscreener.com
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today? - Sahm
Why is Biodexa Pharmaceuticals (BDRX) stock skyrocketing today? - MSN
Biodexa partners with Syngene for MTX240 manufacturing By Investing.com - Investing.com Australia
171.7M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - Stock Titan
109.8M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - stocktitan.net
943.4M Ordinary Shares for Resale; Biodexa (NASDAQ: BDRX) resale filing - stocktitan.net
1.7018B shares for resale by holders — Biodexa (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADS for resale via equity line - Stock Titan
Biodexa’s eRapa Program: Global Expansion and European Gains - StocksToTrade
Biodexa partners with Syngene for MTX240 manufacturing - Investing.com
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies - ChartMill
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
No approved FAP drug: Biodexa opens global eRapa access - Stock Titan
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADSs for resale under equity line - Stock Titan
943.4M Ordinary Shares resale by selling holders (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (BDRX) flags going-concern doubts amid ongoing losses - Stock Titan
Biodexa (NASDAQ: BDRX) grows pipeline but warns on 2026 funding needs - stocktitan.net
Preliminary Results for the Year Ended 31 December 2025 - GlobeNewswire
Biodexa Pharmaceuticals Plc Adr Azioni (BDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):